Adc Therapeutics Ltd Stock News

ADC Therapeutics is a small-cap biotech with an approved antibody-drug conjugate in lymphoma. The company has faced setbacks but has cash on hand and promising clinical data outside of their flagship

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.58 per share versus the Zacks Consensus Estimate of a loss of $0.44. This compares to loss of $0.73 per share a year ago.

LAUSANNE, Switzerland, Aug. 01, 2023 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, August 8, 2023 at 8:30 a.m. E

We expect GSK's specialty products like Cabenuva, Dovato, Bexsero, Breo Ellipta and Shingrix to drive second-quarter sales performance.

ADC Therapeutics SA (ADCT) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement

ADC Therapeutics SA (ADCT) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts i

ADC Therapeutics (ADCT) pauses patient enrollment in a mid-stage study evaluating Zynlonta in combination with rituximab, for patients with previously untreated diffuse large B-cell lymphoma who are u

ADC Therapeutics said on Tuesday it had paused enrollment of new patients in a mid-stage study evaluating its drug Zynlonta along with rituximab for treating a type of blood cancer over safety concern

ADC Therapeutics SA (ADCT) came out with a quarterly loss of $0.74 per share versus the Zacks Consensus Estimate of a loss of $0.80. This compares to loss of $0.36 per share a year ago.

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, May 9, 2023 at 8:30 a.m. EDT to report financi

ADC Therapeutics SA (ADCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings

ADC Therapeutics SA (NYSE:ADCT ) Q4 2022 Results Conference Call February 28, 2023 8:30 AM ET Company Participants Amanda Hamilton - IR Manager Ameet Mallik - CEO Kristen Harrington-Smith - Chief Comm

ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 38.78% and 7.58%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

LAUSANNE, Switzerland--(BUSINESS WIRE)--ADC Therapeutics SA (NYSE: ADCT) today announced that it will host a conference call and live webcast on Tuesday, February 28, 2023 at 8:30 a.m. ET to report fi

Molina Healthcare's (MOH) fourth-quarter results are likely to reflect growth in premiums and Investment income.